• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较肿瘤基因组学鉴定出富含功能性肿瘤起始细胞的乳腺肿瘤。

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

机构信息

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. doi: 10.1073/pnas.1018862108. Epub 2011 Jun 1.

DOI:10.1073/pnas.1018862108
PMID:21633010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3286979/
Abstract

The claudin-low subtype is a recently identified rare molecular subtype of human breast cancer that expresses low levels of tight and adherens junction genes and shows high expression of epithelial-to-mesenchymal transition (EMT) genes. These tumors are enriched in gene expression signatures derived from human tumor-initiating cells (TICs) and human mammary stem cells. Through cross-species analysis, we discovered mouse mammary tumors that have similar gene expression characteristics as human claudin-low tumors and were also enriched for the human TIC signature. Such claudin-low tumors were similarly rare but came from a number of distinct mouse models, including the p53 null transplant model. Here we present a molecular characterization of 50 p53 null mammary tumors compared with other mouse models and human breast tumor subtypes. Similar to human tumors, the murine p53 null tumors fell into multiple molecular subtypes, including two basal-like, a luminal, a claudin-low, and a subtype unique to this model. The claudin-low tumors also showed high gene expression of EMT inducers, low expression of the miR-200 family, and low to absent expression of both claudin 3 and E-cadherin. These murine subtypes also contained distinct genomic DNA copy number changes, some of which are similarly altered in their cognate human subtype counterpart. Finally, limiting dilution transplantation revealed that p53 null claudin-low tumors are highly enriched for TICs compared with the more common adenocarcinomas arising in the same model, thus providing a unique preclinical mouse model to investigate the therapeutic response of TICs.

摘要

Claudin-low 亚型是最近鉴定出的一种罕见的人乳腺癌分子亚型,其特点是紧密连接和黏附连接基因表达水平低,上皮间质转化 (EMT) 基因表达水平高。这些肿瘤富含源自人肿瘤起始细胞 (TICs) 和人乳腺干细胞的基因表达特征。通过跨物种分析,我们发现了具有与人 Claudin-low 肿瘤相似基因表达特征的小鼠乳腺肿瘤,并且也富含人 TIC 特征。这种 Claudin-low 肿瘤同样罕见,但来自多种不同的小鼠模型,包括 p53 缺失的移植模型。在此,我们对 50 个 p53 缺失的乳腺肿瘤进行了分子特征分析,与其他小鼠模型和人类乳腺癌肿瘤亚型进行了比较。与人类肿瘤相似,p53 缺失的小鼠肿瘤分为多个分子亚型,包括两个基底样、一个腔样、一个 Claudin-low 样,以及一个仅存在于该模型中的亚型。Claudin-low 肿瘤也表现出 EMT 诱导物的高基因表达、miR-200 家族的低表达,以及 Claudin3 和 E-钙黏蛋白的低表达或缺失。这些小鼠亚型还具有独特的基因组 DNA 拷贝数变化,其中一些在其同源的人类亚型中也有类似的改变。最后,有限稀释移植显示,与同一模型中更为常见的腺癌相比,p53 缺失 Claudin-low 肿瘤中 TICs 高度富集,从而为研究 TICs 的治疗反应提供了一个独特的临床前小鼠模型。

相似文献

1
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.比较肿瘤基因组学鉴定出富含功能性肿瘤起始细胞的乳腺肿瘤。
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. doi: 10.1073/pnas.1018862108. Epub 2011 Jun 1.
2
Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.小鼠乳腺上皮细胞中靶向性Pten缺失加p53-R270H突变可诱导侵袭性的claudin低表达型和基底样乳腺癌。
Breast Cancer Res. 2016 Jan 19;18(1):9. doi: 10.1186/s13058-015-0668-y.
3
Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.Claudin-low 样小鼠乳腺肿瘤表现出与基因组驱动因素解耦的独特转录组模式。
Breast Cancer Res. 2019 Jul 31;21(1):85. doi: 10.1186/s13058-019-1170-8.
4
Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.小鼠乳腺肿瘤的基因组分析确定了p53缺陷型乳腺癌潜在的个性化药物靶点。
Dis Model Mech. 2016 Jul 1;9(7):749-57. doi: 10.1242/dmm.025239. Epub 2016 May 5.
5
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.膳食能量平衡调节 claudin-low 和基底样乳腺肿瘤小鼠模型中的上皮间质转化和肿瘤进展。
Cancer Prev Res (Phila). 2012 Jul;5(7):930-42. doi: 10.1158/1940-6207.CAPR-12-0034. Epub 2012 May 15.
6
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Claudin-low 型乳腺癌的表型和分子特征。
Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.
7
Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.miR-200c在claudin低表达型乳腺癌中的表达改变了干细胞功能,增强了化学敏感性并降低了转移潜能。
Oncogene. 2015 Dec 3;34(49):5997-6006. doi: 10.1038/onc.2015.48. Epub 2015 Mar 9.
8
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.Met 与 p53 缺失协同作用诱导具有 Claudin-low 乳腺癌特征的乳腺肿瘤。
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.
9
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.用于研究内在分子亚型的乳腺癌和正常乳腺组织来源的细胞系的特征。
Breast Cancer Res Treat. 2013 Nov;142(2):237-55. doi: 10.1007/s10549-013-2743-3. Epub 2013 Oct 27.
10
Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.狂躁边缘和 p53 协同抑制间充质干细胞样乳腺癌。
Neoplasia. 2017 Nov;19(11):885-895. doi: 10.1016/j.neo.2017.08.006. Epub 2017 Sep 19.

引用本文的文献

1
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers.抗集落刺激因子1受体(CSF-1R)疗法联合免疫化疗可协调适应性免疫反应,以消除富含巨噬细胞的三阴性乳腺癌。
bioRxiv. 2025 May 6:2025.04.30.651522. doi: 10.1101/2025.04.30.651522.
2
Systemic inflammation in response to radiation drives the genesis of an immunosuppressed tumor microenvironment.对辐射的全身炎症反应驱动了免疫抑制肿瘤微环境的形成。
Neoplasia. 2025 Jun;64:101164. doi: 10.1016/j.neo.2025.101164. Epub 2025 Apr 3.
3
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.IRE1α使双链RNA沉默以防止紫杉烷诱导的三阴性乳腺癌细胞焦亡。
Cell. 2024 Dec 12;187(25):7248-7266.e34. doi: 10.1016/j.cell.2024.09.032. Epub 2024 Oct 16.
4
Aneuploidy as a driver of human cancer.非整倍体作为人类癌症的驱动因素。
Nat Genet. 2024 Oct;56(10):2014-2026. doi: 10.1038/s41588-024-01916-2. Epub 2024 Oct 2.
5
CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.CREB 结合蛋白/P300 溴结构域抑制减少三阴性乳腺癌中的中性粒细胞积累并激活抗肿瘤免疫。
JCI Insight. 2024 Sep 17;9(20):e182621. doi: 10.1172/jci.insight.182621.
6
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.纳米剂型 TLR7/8 激动剂和 PI3Kδ 抑制剂对肿瘤微环境的免疫调节增强了放射治疗的疗效。
Biomaterials. 2025 Jan;312:122750. doi: 10.1016/j.biomaterials.2024.122750. Epub 2024 Aug 8.
7
CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.CBP/P300溴结构域抑制可减少三阴性乳腺癌中的中性粒细胞积聚并激活抗肿瘤免疫。
bioRxiv. 2024 Apr 27:2024.04.25.590983. doi: 10.1101/2024.04.25.590983.
8
GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.GATA3 通过 BRCA1 下游发挥作用,促进 DNA 损伤修复,并抑制乳腺癌去分化。
BMC Biol. 2024 Apr 16;22(1):85. doi: 10.1186/s12915-024-01881-6.
9
Benzophenone-3 alters expression of genes encoding vascularization and epithelial-mesenchymal transition functions during Trp53-null mammary tumorigenesis.二苯甲酮-3 在 Trp53 缺失型乳腺肿瘤发生过程中改变了编码血管生成和上皮-间充质转化功能的基因表达。
Food Chem Toxicol. 2024 Apr;186:114540. doi: 10.1016/j.fct.2024.114540. Epub 2024 Feb 20.
10
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.靶向 eIF4A 会触发干扰素反应,与化疗协同作用,抑制三阴性乳腺癌。
J Clin Invest. 2023 Dec 15;133(24):e172503. doi: 10.1172/JCI172503.

本文引用的文献

1
Cells of origin in cancer.癌症起源细胞。
Nature. 2011 Jan 20;469(7330):314-22. doi: 10.1038/nature09781.
2
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.肌醇多聚磷酸 4-磷酸酶 II 调节 PI3K/Akt 信号通路,并且在人基底样乳腺癌中缺失。
Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22231-6. doi: 10.1073/pnas.1015245107. Epub 2010 Dec 2.
3
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Claudin-low 型乳腺癌的表型和分子特征。
Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.
4
s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue.s-SHIP 启动子表达标志着发育中的小鼠乳腺组织中的激活干细胞。
Genes Dev. 2010 Sep 1;24(17):1882-92. doi: 10.1101/gad.1932810.
5
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.BRCA1 基底样乳腺癌起源于腔上皮祖细胞,而不是基底干细胞。
Cell Stem Cell. 2010 Sep 3;7(3):403-17. doi: 10.1016/j.stem.2010.07.010.
6
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.核心上皮-间充质转化相互作用组基因表达特征与 Claudin-low 和化生型乳腺癌亚型相关。
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16.
7
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
8
Small players with big roles: microRNAs as targets to inhibit breast cancer progression.小角色,大作用:微小 RNA 作为抑制乳腺癌进展的靶点。
Curr Drug Targets. 2010 Sep;11(9):1059-73. doi: 10.2174/138945010792006762.
9
The pathology of EMT in mouse mammary tumorigenesis.EMT 在小鼠乳腺肿瘤发生中的病理学研究。
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):225-33. doi: 10.1007/s10911-010-9184-y. Epub 2010 Jun 4.
10
Selective targeting of radiation-resistant tumor-initiating cells.选择性靶向辐射抵抗性肿瘤起始细胞。
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3522-7. doi: 10.1073/pnas.0910179107. Epub 2010 Feb 3.